Pathology: la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | ||
| MK-8669-064, 2017 | QUILT-2.015, 2013 | ||
| dalotuzumab plus ridaforolimus plus exemestane | 1 | T1 | |
| ganitumab plus endocrine therapy | 1 | T1 | |
| exemestane plus ridaforolimus | 0 | T0 | |
| endocrine therapy | 0 | T0 |